A
Allied Corp
OTC:ALID
Allied Corp
OTC:ALID
Price:
0.0005
USD
Market Closed
Market Cap:
$115.5
Allied Corp
Research & Development
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Allied Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Allied Corp
OTC:ALID
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Research & Development
-$631m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Research & Development
-$4.1m
|
CAGR 3-Years
38%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Research & Development
-$105.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-152%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Research & Development
-CA$27.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-26%
|
|
No Stocks Found
Allied Corp
Glance View
Allied Corp. operates as a medical cannabis company. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2018-12-04. The firm is focused on creating and providing health solutions to address medical mental health issues. The firm focuses to discover medical technologies, which are cannabis derived to target full scope therapy and support for trauma survivors, military veterans and first responders. Its functional mushroom formulation targets major depression and anxiety. The firm is also engaged in research and development activities in the psilocybin space and holds formulations.
ALID
Intrinsic Value
Not Available
